Arcutis Biotherapeutics logo

Arcutis Biotherapeutics

ARQT | NASDAQ
Chart Builder DCF Calculator
$27.15
-$1.11 (-3.93%)
At close: Nov 16, 2026, 4:00 PM ET
$25.79
-$1.36 (-5.01%)
After-hours: Nov 16, 2026, 7:32 PM ET
-3.93%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
65.8
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #85/1021 (Top 8%)

Key Statistics

Market Data

Market Cap $3.43B
1D Range
27.03 28.40
52W Range
19.50 34.05

Valuation (TTM)

PE 129.29
PB 14.07
EV/EBITDA 73.36

Valuation (NTM)

Forward PE 100.93
Forward PEG -0.49
Price Target $40.00
Loading financial charts...

Profile

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151...

Sector Healthcare
Industry Biotechnology
Employees 354
IPO Date Jan 31, 2020
Fiscal Year January - December

Latest News

Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting

3 days ago · globenewswire.com

Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis

12 days ago · globenewswire.com

Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript
Arcutis Biotherapeutics Q3 Earnings Call Highlights

12 days ago · marketbeat.com

Arcutis Biotherapeutics Q3 Earnings Call Highlights
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates

12 days ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth

20 days ago · zacks.com

Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Appoints Rob Scott, MD to Board of Directors

20 days ago · globenewswire.com

Arcutis Appoints Rob Scott, MD to Board of Directors
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

20 days ago · globenewswire.com

Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026

26 days ago · globenewswire.com

Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
Why Is Arcutis Biotherapeutics Stock Surging Thursday?

1 month ago · benzinga.com

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Earnings

Latest Earnings
Nov 4, 2026
EPS
$0.06
Miss -66.67%
REV
$143.92M
Beat +0.93%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$40.00
Upside
+47.33%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.